Sökning: "Alzheimer’s disease"
Visar resultat 16 - 20 av 579 avhandlingar innehållade orden Alzheimer’s disease.
16. Enhancing the therapeutic effect of biological drugs with protein engineering : Focusing on pre-clinical Alzheimer’s disease therapy
Sammanfattning : Aggregation of the amyloid-β peptide (Aβ) is one of the main pathological hallmarks in Alzheimer’s disease (AD). The soluble Aβ aggregates (oligomers and protofibrils) have shown to be the most harmful species. Hence, targeting these aggregates can be of therapeutic potential. LÄS MER
17. Observations on cerebral amyloid angiopathy and microvascular pathology in Alzheimer's disease and vascular dementia
Sammanfattning : Dementia is a state of permanent loss of cognitive function, most commonly affecting the elderly. With a rapidly growing aged population, the spectrum of disorders that lead to dementia is exerting an ever-increasing toll on patients, families and society alike. The most common dementing disorders are Alzheimer's disease and vascular dementia. LÄS MER
18. Detection of Differentially Expressed Genes in Alzheimer's Disease : Regulator of G-protein Signalling 4: A Novel Mediator of APP Processing
Sammanfattning : Alzheimer’s disease is a neurodegenerative disease characterised by progressive memory deterioration and cognitive impairment. Pathological hallmarks are extracellular senile plaques, neurofibrillary tangles and neuron loss. Senile plaques are produced through altered processing of the membrane-bound protein APP. LÄS MER
19. Pathophysiological Mechanisms and Diagnostic Markers in Alzheimer’s Disease
Sammanfattning : Alzheimer’s disease (AD), the most common cause of dementia, is a growing concern. As the life expectancy increases across the globe, the number of affected people is estimated to reach 100 million by 2050. LÄS MER
20. Biomarkers for Alzheimer's disease and the APOE polymorphism
Sammanfattning : Alzheimer’s disease (AD) is the most common form of dementia and cerebrospinal fluid (CSF) biomarkers reflecting the core pathology of AD are now widely used for diagnosis making, in particular β-amyloid[1-42] (Aβ42) reflecting amyloid plaque pathology, phosphorylated tau (P-tau) reflecting neurofibrillary tangle pathology and total tau (T-tau) reflecting general neurodegeneration. In addition, blood-based biomarkers for AD are in the pipeline with recent studies showing promising diagnostic potential. LÄS MER